XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Notes)
 9 Months Ended
Sep. 30, 2021
Acquisitions, Divestitures and Other Arrangements [Abstract]  
Divestitures, Licensing and Other Arrangements [Text Block] DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS
Divestitures

The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).
Three Months Ended September 30,
Net Proceeds(a)
Divestiture (Gains)/LossesRoyalty Income
Dollars in Millions202120202021202020212020
Diabetes Business$153 $129 $— $— $(159)$(148)
Erbitux* Business
4 3 — — — — 
Manufacturing Operations27 — — — — — 
Mature Brands and Other4 41 2 1 (1)(44)
Total$188 $173 $2 $1 $(160)$(192)
Nine Months Ended September 30,
Net Proceeds(a)
Divestiture (Gains)/LossesRoyalty Income
Dollars in Millions202120202021202020212020
Diabetes Business$449 $409 $— $— $(445)$(404)
Erbitux* Business
10 10 — — — — 
Manufacturing Operations50 10 — (1)— — 
Plavix* and Avapro*/Avalide*
5 7 — (12)— — 
Mature Brands and Other56 73 (9)7 (2)(76)
Total$570 $509 $(9)$(6)$(447)$(480)
(a)    Includes royalties received subsequent to the related sale of the asset or business.

Licensing and Other Arrangements

The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, up-front licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in Millions2021202020212020
Keytruda* royalties
$(215)$(176)$(611)$(492)
Tecentriq* royalties
(22)— (67)— 
Up-front licensing fees— — — (30)
Contingent milestone income(10)(16)(12)(62)
Amortization of deferred income3 (14)(27)(44)
Other royalties(21)(5)(33)(16)
Total$(265)$(211)$(750)$(644)

Agenus

In the third quarter of 2021, BMS obtained a global exclusive license to Agenus’ proprietary AGEN1777 bispecific antibody program that blocks TIGIT and an additional target. AGEN1777 is being studied in oncology and a Phase I clinical trial was initiated in October 2021. BMS will be responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding and manufacturing. The transaction included an up-front payment of $200 million which was included in Research and development expense and Agenus is eligible to receive contingent development, regulatory and sales-based milestones up to $1.4 billion as well as royalties on global net sales.